SAB Biotherapeutics (SABS)
(Real Time Quote from BATS)
$4.25 USD
0.00 (0.00%)
Updated Apr 29, 2024 03:30 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for SAB Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 24 | 61 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 2 | 24 | 61 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 40 | 53 | 74 | 0 | 0 |
Income After Depreciation & Amortization | -38 | -29 | -13 | 0 | 0 |
Non-Operating Income | -4 | 11 | -3 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -42 | -19 | -17 | 0 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -42 | -19 | -17 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -42 | -19 | -17 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -34 | -26 | -12 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 4 | 3 | 2 | 0 | NA |
Income After Depreciation & Amortization | -38 | -29 | -13 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.52 | NA | 2.73 | NA | NA |
Diluted EPS Before Non-Recurring Items | -7.64 | NA | -6.30 | NA | NA |
Diluted Net EPS (GAAP) | -7.64 | -4.30 | -6.30 | NA | NA |
Fiscal Year end for SAB Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.31 | 1.27 | 0.09 | 0.58 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.31 | 1.27 | 0.09 | 0.58 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 19.18 | 6.59 | 6.56 | 7.99 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -18.87 | -5.32 | -6.47 | -7.41 |
Non-Operating Income | NA | -3.91 | 0.29 | -0.33 | 0.14 |
Interest Expense | NA | 0.08 | 0.07 | 0.08 | 0.09 |
Pretax Income | NA | -22.86 | -5.10 | -6.88 | -7.35 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -22.86 | -5.10 | -6.88 | -7.35 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -22.86 | -5.10 | -6.88 | -7.35 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 5.24 | 5.04 | 5.04 |
Diluted EPS Before Non-Recurring Items | NA | NA | -1.00 | -1.40 | -1.50 |
Diluted Net EPS (GAAP) | NA | -3.74 | -1.00 | -1.40 | -1.50 |